MXD4

Across TCGA pan-cancer cohorts, MXD4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MXD4 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MXD4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MXD4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, LSCC, and GBM are the cancer types where MXD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.630	0.195	.011	17	view →
LSCC	OS	Tertile	All	0.684	1.000	.006	12	view →
GBM	OS	Tertile	All	0.797	0.405	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MXD4–LUAD (DFS)

Open the LUAD breakdown →